Statin drug interactions and related adverse reactions: an update

References

• Catapano AL, Graham I, De Backer G. et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Gu Q, Paulose-Ram R, Burt VL, et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014;177:1–8.
   PubMedGoogle Scholar
• Du Souich P, Roederer G, Dufour R. Myotoxicity of statins: mechanism of action. Pharmacol Ther. 2017;175:1–16.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022.
   PubMed Web of Science ®Google Scholar
• Benes LB, Bassi NS, Davidson MH. The risk of hepatotoxicity, new onset diabetes and rhabdomyolysis in the era of high-intensity statin therapy: does statin type matter? Prog Cardiovasc Dis. 2016;59:145–152.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11:933–946.
   PubMed Web of Science ®Google Scholar
• Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 1988;62:28J–34J.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Saseen JJ, Page RL 2nd. et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart association. Circulation. 2016;134:e468–e495.
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–428.
   PubMed Web of Science ®Google Scholar
• Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ. 1999;161:1266–1267.
   PubMed Web of Science ®Google Scholar
• Venturini CD, Engroff P, Ely LS, et al. Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clinics (Sao Paulo). 2011;66:1867–1872.
   PubMed Web of Science ®Google Scholar
• Santos TRA, Silveira EA, Pereira LV, et al. Potential drug–drug interactions in older adults: A populationbased study. Geriatric Gerontology International 2017;[ Epub ahead of print]
   Google Scholar
• Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364–377.
   PubMed Web of Science ®Google Scholar
• Hanlon JT, Perera S, Newman AB, et al. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults. J Clin Pharm Ther. 2017;42:228–233.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(III):50–57.
   Google Scholar
• Corsini A, Bellosta S. Drug-drug interaction with statins. Expert Rev Clin Pharmacol. 2008;1:105–113.
   PubMed Web of Science ®Google Scholar
• Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin. 2011;27:1551–1562.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs. 2010;11:323–332.
   PubMed Web of Science ®Google Scholar
• Cilla DD Jr., Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687–695.
   PubMed Web of Science ®Google Scholar
• Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97:27C–31C.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama. 2003;289:1681–1690.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations. FDA. 2012. [cited 2017 Aug 16]. Available at: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm
   Google Scholar
• Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5:703–729.
   PubMed Web of Science ®Google Scholar
• Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27–41.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the “rank order” approach. Drug Metabolism Letter. 2007;1:31–35.
   PubMedGoogle Scholar
• Arrigoni E, Del Re M, Fidilio L. et al. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017;18:104.
   PubMed Web of Science ®Google Scholar
• Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15:415–421.
   PubMed Web of Science ®Google Scholar
• Hou Q, Li S, Li L, et al. Association between SLCO1B1 Gene T521C polymorphism and statin-related myopathy risk: a meta-analysis of case-control studies. Medicine (Baltimore). 2015;94:e1268.
   PubMed Web of Science ®Google Scholar
• Oshiro C, Mangravite L, Klein T, et al. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20:211–216.
   PubMed Web of Science ®Google Scholar
• Kim CO, Oh ES, Kim H, et al. Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Drug Des Devel Ther. 2017;11:503–512.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6:400–408.
   PubMed Web of Science ®Google Scholar
• Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87:130–133.
   PubMed Web of Science ®Google Scholar
• Lee HK, Hu M, Lui S, et al. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013;14:1283–1294.
   PubMed Web of Science ®Google Scholar
• Wiggins BS, Lamprecht DG Jr., Page RL 2nd. et al. Recommendations for managing drug-drug interactions with statins and HIV Medications. Am J Cardiovasc Drugs. 2017. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. FDA. 2012. [cited 2017 Aug 16]. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm293877.htm
   Google Scholar
• Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005;96;(44K–49K): 34K–35K. discussion.
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;2014(129):S1–45.
   Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Cholib 145 mg/20 mg film coated tablets. Mylan. 2016. [cited 2017 Aug 18]. Available at: https://www.medicines.org.uk/emc/medicine/31559
   Google Scholar
• Amgen. Ivabradine, Corlanor [package insert]. Thousand Oaks, CA; 2015.
   Google Scholar
• European Medicines Agency. Ivabradine approval. EMEA/H/C/000597. EMA. 2005. [cited 2017 Aug 20]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000597/human_med_000995.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Novartis. Entresto. Summary of product characteristics. 2015
   Google Scholar
• European Medicines Agency. Sacubitril/valsartan approval. EMEA/H/C/004062. EMA. 2015. [cited 2017 Aug 20]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004062/human_med_001929.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Lin W, Ji T, Einolf H, et al. Evaluation of drug-drug interaction potential between sacubitril/valsartan (LCZ696) and statins using a physiologically based pharmacokinetic model. J Pharm Sci. 2017;106:1439–1451.
   PubMed Web of Science ®Google Scholar
• Antoniou T, Macdonald EM, Yao Z, et al. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ. 2017;189:E4–E10.
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33:537–546.
   PubMed Web of Science ®Google Scholar
• Gelosa P, Castiglioni L, Racagni G, et al. Pharmacokinetic interactions of the non-vitamin K oral anticoagulants (NOACs). Pharmacological Research 2017; Manuscript in preparation
   Google Scholar
• AstraZeneca, Ticagrelor [package insert]. 2014.
   Google Scholar
• Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477–487.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681–1709.
   PubMed Web of Science ®Google Scholar
• Banakh I, Haji K, Kung R, et al. Severe rhabdomyolysis due to presumed drug interactions between atorvastatin with amlodipine and ticagrelor. Case Rep Crit Care. 2017;2017:3801819.
   PubMedGoogle Scholar
• Kido K, Wheeler MB, Seratnahaei A, et al. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc. 2003;2015(55):320–323.
   Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011;57:1251–1263.
   PubMed Web of Science ®Google Scholar
• Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422–433.
   PubMed Web of Science ®Google Scholar
• Park CG, Lee H, Choi JW, et al. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther. 2010;48:497–503.
   PubMed Web of Science ®Google Scholar
• Kellick KA, Bottorff M, Toth PP, et al. A clinician’s guide to statin drug-drug interactions. J Clin Lipidol. 2014;8:S30–46.
   PubMed Web of Science ®Google Scholar
• Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359–372.
   PubMed Web of Science ®Google Scholar
• Ferri N, Bellosta S, Baldessin L, et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–599.
   PubMed Web of Science ®Google Scholar
• Roskos LK, Kellermann SA, and Foon KA, Human antiglobulin responses, in Measuring immunity: basic science and clinical practice, M.T. Lotze and A.W. Thompson, Editors. 2005, Elsevier Academic Press: San Diego, CA, USA. p. 172–186.
   Google Scholar
• Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44:707–715.
   PubMed Web of Science ®Google Scholar
• Zhang X, Schmitt C, Grange S, et al. Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo. Clin. Pharmacol. Ther. 2007;85:S59.
   Web of Science ®Google Scholar
• Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35:1687–1693.
   PubMed Web of Science ®Google Scholar
• Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012;32:2601–2604.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Zhang X, et al. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89:735–740.
   PubMed Web of Science ®Google Scholar
• Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229:174–181.
   PubMed Web of Science ®Google Scholar
• Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–89.
   PubMedGoogle Scholar
• Alirocumab, Summary of product characteristics. EMA. 2017a. [cited 2017 Aug 10]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003882/human_med_001915.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Evolocumab, Summary of product characteristics. EMA. 2017b. [cited 2017 Aug 10]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003766/human_med_001890.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Cholesterol-lowering drugs get labeling changes. FDA. 2015. [cited 2017 Oct 3]. Available at: https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm290856.htm
   Google Scholar
• Corsini A, Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol. 2013;53:463–474.
   PubMed Web of Science ®Google Scholar
• Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11:477–505, v.
   PubMedGoogle Scholar
• Lopez JL, Tayek JA. Voriconazole-induced hepatitis via simvastatin- and lansoprazole-mediated drug interactions: a case report and review of the literature. Drug Metab Dispos. 2016;44:124–126.
   PubMed Web of Science ®Google Scholar
• Groll AH, Kolve H, Ehlert K, et al. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother. 2004;53:113–114.
   PubMed Web of Science ®Google Scholar
• Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235–243.
   PubMed Web of Science ®Google Scholar
• Bastida C, Also MA, Pericas JM, et al. [Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?]. Enferm Infecc Microbiol Clin. 2014;32:579–582.
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347–356.
   PubMed Web of Science ®Google Scholar
• Ivandic E, Basic-Jukic N. Liver damage caused by atorvastatin and cyclosporine in patients with renal transplant. Acta Med Croatica. 2014;68:175–178.
   PubMedGoogle Scholar
• Schuler J, Duckelmann C, Beindl W, et al. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr. 2008;120:733–741.
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205.
   PubMed Web of Science ®Google Scholar
• McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331–1336.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–450.
   PubMed Web of Science ®Google Scholar
• Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An Update. Clin Pharmacokinet. 1997;33:302–312.
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13:57–65.
   PubMed Web of Science ®Google Scholar
• Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83.
   PubMed Web of Science ®Google Scholar
• Wynne HA, Blagburn J. Drug treatment in an ageing population: practical implications. Maturitas. 2010;66:246–250.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Health, United States, 2015: with special feature on racial and ethnic health disparities. National  Center for Health Statistics. Hyattsville, MD, 2016
   Google Scholar
• Egger SS, Ratz Bravo AE, Hess L, et al. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging. 2007;24:429–440.
   PubMed Web of Science ®Google Scholar
• Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17:123–132.
   PubMedGoogle Scholar
• Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–622.
   PubMed Web of Science ®Google Scholar
• Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr. 2009;50:54–64.
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clin Infect Dis. 2003;37 :613–27.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9:72–81.
   PubMed Web of Science ®Google Scholar
• Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52–60.
   PubMed Web of Science ®Google Scholar
• Drewe J, Gutmann H, Fricker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57:1147–1152.
   PubMed Web of Science ®Google Scholar
• Perloff MD, Von Moltke LL, Marchand JE, et al. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001;90:1829–1837.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195–1211.
   PubMed Web of Science ®Google Scholar
• Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med. 2010;268:530–539.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565–581.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016). Can J Cardiol. 2016;32:S35–65.
   PubMed Web of Science ®Google Scholar